生物评估和分子对接研究,准备的基衍生物作为潜在的抗阿尔茨海默症药物
E N Agbo1, B K Maluleke2, S Gildenhuys3
1Department of Chemistry, School of Physical and Mineral Sciences, University of Limpopo, Limpopo, Sovenga, 0727, South Africa. emmanuel.agbo@ul.ac.za.
Scientific reports
|October 21, 2025
概括
新的化衍生物显示出作为阿尔茨海默氏症 (AD) 的多目标药物具有前途. 化合物3e有效抑制胆酶,环氧基酶-2和脂氧基酶,这表明AD药物开发的潜力.
科学领域:
- 神经科学是一个神经科学.
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,与乙胆下降和粉样β斑块积累有关.
- 抑制胆酶,β-分泌酶,循环氧化酶 (COX) 和脂氧化酶 (LOX) 等酶是管理AD症状的关键策略.
- ,硫和化合物以其潜在的酶抑制活性而闻名.
研究的目的:
- 合成新型基和它们的基衍生物.
- 评估这些合成化合物作为潜在的阿尔茨海默氏症多目标抑制剂.
- 评估它们对胆酶,β-分泌酶,COX-2和LOX-5酶的抑制作用.
主要方法:
- 合成来自2,4-二氧基的基和基衍生物.
- 在体外酶测试以确定对胆酶,β-分泌酶,COX-2和LOX-5的抑制活性.
- 酶动力学和分子对接研究,以阐明机制.
主要成果:
- 衍生物3c,3e和3g显示出胆酶和β-分泌酶的显著抑制.
- 化合物3a,3b和3e表现出良好的COX-2抑制活性,而其他化合物表现出弱的抗炎作用.
- 化合物3e对胆酶,COX和LOX表现出显著的抑制活性,动力学和对接表明混合模式的抑制.
结论:
- 基石衍生物,特别是化合物3e,显示出作为阿尔茨海默氏症多标药物候选者的潜力.
- 化合物3e对多个关键酶的显著抑制提供了一个有前途的治疗途径.
- 进一步调查3e作为AD治疗的化合物是有必要的.
关键词:
2,4-二氧乙烯胺的二,4-二氧乙烯.这是一种抗阿尔茨海默氏症的药物.胆化酶是一种胆酶.循环氧化基因酶 (Cyclooxygenase) 是一种酶动力学 酶动力学脂氧基因酶的使用方法分子对接是分子对接.这是一个秘密的秘密.更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.5K
15:23Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease
Published on: May 13, 2010
19.9K
相关概念视频
Alzheimer's Disease: Treatment
811
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
811
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
552
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
552
